

## Company Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing innovative therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

## Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development

Aug 7 2019, 6:30 AM EDT

## Rexahn Announces Move to Nasdaq

May 28 2019, 4:10 PM EDT

## Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

May 13 2019, 8:00 AM EDT

## Stock Overview

Symbol	REXN
Exchange	Nasdaq
Market Cap	8.88m
Last Price	\$2.21
52-Week	\$2.03 - \$23.280001

09/20/2019 04:00 PM EDT

## Investor Relations

[ir@rexahn.com](mailto:ir@rexahn.com)

## Management Team

### Douglas J. Swirsky

President and Chief Executive Officer

### Lisa Nolan, Ph.D.

Chief Business Officer

### DJ Kim, Ph.D.

Vice President and Head of Research and Development

## Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road  
Suite 455  
Rockville, MD 20850

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.